TBP (TATA-Box Binding Protein) is a general transcription factor essential for RNA polymerase II-mediated transcription initiation. Encoded by the TBP gene located on chromosome 6q27, this protein plays a fundamental role in regulating gene expression across all eukaryotic cells. TBP is particularly notable in neurodegeneration research due to its involvement in multiple polyglutamine diseases, most notably spinocerebellar ataxia type 17 (SCA17), and its broader implications in transcriptional dysfunction observed in Alzheimer's disease and Huntington's disease. [1]
| Property | Value |
|---|---|
| Gene Symbol | TBP |
| Full Name | TATA-Box Binding Protein |
| Chr Location | 6q27 |
| NCBI Gene ID | 6908 |
| OMIM ID | 600075 |
| Ensembl ID | ENSG00000112592 |
| UniProt ID | P20226 |
| Encoded Protein | TATA-Binding Protein |
| Associated Diseases | Huntington's disease, spinocerebellar ataxia type 17, Alzheimer's disease |
The TBP gene spans approximately 32 kb and consists of 8 exons encoding a 339-amino acid protein. The gene contains a polymorphic CAG repeat in the first exon that encodes a polyglutamine (polyQ) tract in the N-terminal domain. This polyQ tract is the critical region implicated in disease pathogenesis.
The TBP protein contains several distinct functional domains:
N-terminal domain (aa 1-159): Glutamine-rich region containing the polymorphic polyQ tract. This domain is involved in protein-protein interactions with various transcription cofactors and can undergo post-translational modifications including phosphorylation, sumoylation, and acetylation.
C-terminal domain (aa 160-339): The conserved "saddle-shaped" DNA-binding domain that binds specifically to the TATA box sequence (TATAAA) in gene promoters. This domain is highly conserved across eukaryotes and is essential for TBP's function as a general transcription factor. [2]
TBP performs several critical cellular functions:
Transcription Initiation: TBP is the DNA-binding component of the transcription factor IID (TFIID) complex. It binds to the TATA box in promoter regions and facilitates the recruitment of RNA polymerase II and other general transcription factors to form the pre-initiation complex (PIC).
Promoter Recognition: TBP provides promoter specificity by recognizing TATA box-containing genes. Estimates suggest approximately 10-20% of human promoters contain canonical TATA boxes.
Transcriptional Regulation: Beyond basal transcription, TBP interacts with various transcriptional activators and repressors to modulate gene expression in response to cellular signals.
Transcription-Coupled DNA Repair: TBP is involved in the transcription-coupled nucleotide excision repair (TC-NER) pathway, particularly for genes actively transcribed by RNA polymerase II.
Mitochondrial Transcription: TBP also functions in mitochondrial DNA transcription as part of the mitochondrial transcription factor A (TFAM) complex. [3]
TBP is ubiquitously expressed as a housekeeping gene, with highest levels in metabolically active tissues:
| Tissue Type | Expression Level |
|---|---|
| Brain (cortex, hippocampus, cerebellum) | Highest |
| Liver | High |
| Kidney | High |
| Heart | Moderate |
| Skeletal muscle | Moderate |
| Most other tissues | Low-moderate |
In the central nervous system, TBP is expressed in:
The Allen Brain Atlas demonstrates particularly high TBP expression in neurons with high transcriptional activity, reflecting the protein's essential role in general transcription.
SCA17 is caused by CAG repeat expansion in the TBP gene, making it a member of the polyglutamine (polyQ) disease family that includes Huntington's disease, spinocerebellar ataxia type 1, and several other ataxias.
The expanded polyQ tract leads to:
SCA17 presents with:
Recent studies have identified:
Although HD is caused by HTT gene mutations, TBP plays a significant role in HD pathogenesis:
Studies have shown that TBP levels and modifications are altered in HD models and patient tissues, suggesting TBP dysfunction contributes to the broader transcriptional dysregulation characteristic of HD. [5]
TBP involvement in Alzheimer's disease relates to:
Research using AD brain tissue and models has demonstrated altered TBP post-translational modifications and nuclear import/export dynamics. [6]
TBP has been associated with Parkinson's disease through:
TBP undergoes several modifications relevant to neurodegeneration:
Phosphorylation: TBP phosphorylation affects its DNA-binding activity and interactions with cofactors. Stress-activated kinases can modify TBP in disease contexts.
Sumoylation: TBP can be sumoylated, and this modification is altered in polyglutamine diseases. Sumoylation affects TBP's transcriptional activity and may influence aggregation.
Acetylation: TBP acetylation modulates its function and can be dysregulated in neurodegeneration.
Several therapeutic strategies targeting TBP are under investigation:
| Approach | Mechanism | Status |
|---|---|---|
| Gene silencing | Reduce mutant TBP expression | Preclinical |
| Aggregation inhibitors | Prevent TBP aggregation | Research |
| Transcriptional modulators | Restore normal transcription | Experimental |
| Protein replacement | Deliver functional TBP | Theoretical |
| Small molecule stabilizers | Stabilize normal TBP conformation | Discovery |
The polyglutamine tract makes TBP an attractive target for:
TBP interacts with numerous proteins relevant to neurodegeneration:
Several model systems have advanced understanding of TBP in neurodegeneration:
Kikuchi et al. SCA17 and TBP (2000). 2000. ↩︎
Friedman et al. [TBP in transcription (2008)](https://doi.org/10.1016/S0092-8674(00). 2008. ↩︎
Benn et al. TBP in neurodegeneration (2008). 2008. ↩︎
Fung et al. SCA17 genotype-phenotype correlations (2023). 2023. ↩︎
Govorov et al. TBP modifications in HD models (2011). 2011. ↩︎
Schneider et al. TBP and transcriptional dysregulation in AD (2019). 2019. ↩︎
Hsieh et al. TBP sumoylation in neurodegeneration (2012). 2012. ↩︎
Fujigasaki et al. SCA17 transgene models (2001). 2001. ↩︎